University at Buffalo - The State University of New York
Skip to Content
Type 1 Diabetes TrialNet Study Group[Corporate Author] - PubMed - NCBI
Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes.

Ismail HM, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2017 Sep 27. doi: 10.1007/s00125-017-4453-6. [Epub ahead of print]

PMID:
28956083
2.

Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests.

Sanda S; Type 1 Diabetes TrialNet Study Group.

Pediatr Diabetes. 2017 Jul 14. doi: 10.1111/pedi.12542. [Epub ahead of print]

PMID:
28707353
3.

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.

Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2881-2886. doi: 10.1210/jc.2017-00569.

PMID:
28531305
4.

Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?

Steck AK, Xu P, Geyer S, Redondo MJ, Antinozzi P, Wentworth JM, Sosenko J, Onengut-Gumuscu S, Chen WM, Rich SS, Pugliese A; Type 1 Diabetes TrialNet Study Group.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2873-2880. doi: 10.1210/jc.2016-4003.

PMID:
28520980
5.

Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study.

Liu Y, Rafkin LE, Matheson D, Henderson C, Boulware D, Besser REJ, Ferrara C, Yu L, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group.

Diabet Med. 2017 Jul;34(7):934-937. doi: 10.1111/dme.13338. Epub 2017 Mar 8.

PMID:
28226181
6.

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?

Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ, Rodriguez H, Moran A, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2017 May;40(5):698-701. doi: 10.2337/dc16-2331. Epub 2017 Feb 15.

PMID:
28202550
7.

A model-based approach to sample size estimation in recent onset type 1 diabetes.

Bundy BN, Krischer JP; Type 1 Diabetes TrialNet Study Group.

Diabetes Metab Res Rev. 2016 Nov;32(8):827-834. doi: 10.1002/dmrr.2800. Epub 2016 Apr 21.

PMID:
26991448
8.

GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.

Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2017 Jan;60(1):43-49. Epub 2016 Oct 4.

PMID:
27704166
9.

The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.

Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC; Type 1 Diabetes TrialNet Study Group.

J Immunol. 2016 Oct 15;197(8):3076-3085. Epub 2016 Sep 21.

10.

Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

Fouts A, Pyle L, Yu L, Miao D, Michels A, Krischer J, Sosenko J, Gottlieb P, Steck AK; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2016 Oct;39(10):1738-44. doi: 10.2337/dc16-0302. Epub 2016 Jul 25.

11.

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.

Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2016 Oct;39(10):1664-70. doi: 10.2337/dc16-0360. Epub 2016 Jul 15.

12.

Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis.

Xu P, Krischer JP; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2016 Jun;39(6):1036-44. doi: 10.2337/dc15-2292. Epub 2016 Apr 12.

13.

A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes.

Moya R, Robertson HK, Payne D, Narsale A, Koziol J; Type 1 Diabetes TrialNet Study Group, Davies JD.

Clin Immunol. 2016 May;166-167:72-80. doi: 10.1016/j.clim.2016.04.012. Epub 2016 Apr 22.

14.

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.

Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19.

15.

HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression.

Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L, Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS, Sosenko JM; Type 1 Diabetes TrialNet Study Group.

Diabetes. 2016 Apr;65(4):1109-19. doi: 10.2337/db15-1105. Epub 2016 Jan 28.

16.

The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes.

Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2016 Mar;59(3):542-9. doi: 10.1007/s00125-015-3830-2. Epub 2015 Dec 16.

17.

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429. Review.

18.

Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.

Loechelt BJ, Green M, Gottlieb PA, Blumberg E, Weinberg A, Quinlan S, Baden LR; Type 1 Diabetes TrialNet Study Group.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):198-204. doi: 10.1093/jpids/piu055. Epub 2014 Jun 26.

19.

Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective.

Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Metab Res Rev. 2015 Sep;31(6):588-94. doi: 10.1002/dmrr.2643. Epub 2015 Apr 23.

20.

β cell death and dysfunction during type 1 diabetes development in at-risk individuals.

Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP; Type 1 Diabetes TrialNet Study Group.

J Clin Invest. 2015 Mar 2;125(3):1163-73. doi: 10.1172/JCI78142. Epub 2015 Feb 2.

Supplemental Content

Loading ...
Support Center